%0 Journal Article
%T Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease.
%A Mayrand L
%A Elie J
%A Pinhas Y
%A Rignault-Bricard R
%A Taylor M
%A Brice J
%A de Montalembert M
%A Heilbronner C
%A Beranger A
%A Angyalosy S
%A Chhun S
%A Maciel TT
%A Hermine O
%A Allali S
%J Br J Haematol
%V 205
%N 1
%D 2024 Jul 23
%M 38783629
%F 8.615
%R 10.1111/bjh.19561
%X Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.